NasdaqGS:AMRXPharmaceuticals
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story
Amneal Pharmaceuticals (NasdaqGS:AMRX) has agreed to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform.
The transaction is expected to accelerate Amneal's biosimilar pipeline and support multiple planned biosimilar launches over the coming years.
The combination brings together Kashiv's development capabilities with Amneal's commercial infrastructure and established generics franchise.
Amneal Pharmaceuticals, trading at around $12.52, has seen a very large...